Oral ketamine in paediatric non-convulsive status epilepticus

Seizure

Volumn 12, Issue 7, 2003, Pages 483-489

  Mewasingh, L D ^a   Seekhara T ^a   Aeby, A ^a   Christiaens, F J C ^a   Dan, B ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Benzodiazepines; GABA; Ketamine; NMDA; Non convulsive status epilepticus; Refractory seizures

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOSTEROID; KETAMINE; LORAZEPAM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRAZEPAM; PHENOBARBITAL; PREDNISOLONE; STEROID; VIGABATRIN;

ARTICLE; BODY WEIGHT DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEMALE; HUMAN; HYPERTENSION; LENNOX GASTAUT SYNDROME; MALE; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 0141493917     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(03)00028-1     Document Type: Article

References (22)

1. Krumholz, A., Sung, G. Y., Fisher, R. S. et al. Complex partial status epilepticus accompanied by serious morbidity and mortality. Neurology 1995; 45: 1449-1504.
2. Hoffmann-Riem, M., Diener, W., Benninger, C. et al. Nonconvulsive status epilepticus - a possible cause of mental retardation in patients with Lennox-Gastaut Syndrome. Neuropediatrics 2000; 31: 169-174.
3. Stores, G., Zaiwalla, Z., Styles, E. and Hoshikam, A. Nonconvulsive status epilepticus. Archives of Disease in Childhood 1995; 73: 106-111.
4. Kaplan, P. W. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: "the cure may be worse than the disease"). Neurophysiologie Clinique 2000; 30: 377-382.
5. Sheth, R. D. and Gidal, B. E. Refractory status epilepticus: response to ketamine. Neurology 1998; 51: 1765-1766.
6. Boyd, S. G. and Dan, B. Cortical sensitivity in refractory status epilepticus. Clinical Neurophysiology 2000; 111 (S1): S156-S164.
7. Fitzgibbon, E. J., Hall, P., Schroder, C., Seely, J. and Viola, R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes. A strategy for conversion from parenteral to oral ketamine. Journal of Pain and Symptom Management 2002; 23: 165-170.
8. A receptor function in CA1 pyramidal neurons. Annals of Neurology 1995; 38: 893-900.
9. Rice, A. C. and DeLorenzo, R. J. N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. Neuroscience 1999; 93: 117-123.
10. Borris, D. J., Bertram, E. H. and Kapur, J. Ketamine controls prolonged status epilepticus. Epilepsy Research 2000; 42: 117-122.
11. Halonen, T., Nissinen, J. and Pitkanen, A. Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. Neuropharmacology 2001; 40: 536-550.
12. Kullmann, D. M. and Semyanov, A. Glutamatergic modulation of GABAergic signaling among hippocampic interneurons: novel mechanisms regulating hippocampal excitability. Epilepsia 2002; 45 (Suppl. 5): 174-178.
13. Treiman, D. M., Walton, N. Y. and Kendrick, C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Research 1990; 5: 49-60.
14. Nowack, W. J. and Shaikh, I. A. Progression of electroclinical changes in complex partial status epilepticus: filling in the blanks. Clinical Electroencephalography 1999; 30: 5-8.
15. Wasterlain, C. G., Liu, H., Mazarati, A. M. et al. Self-sustaining status epilepticus: a condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other neuromodulators. Epilepsia 2000; 41 (Suppl. 6): S134-S143.
16. Mazarati, A. M. and Wasterlain, C. G. N-methyl-D-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neuroscience Letters 1999; 265: 187-190.
17. Bertram, E. H. and Lothman, E. W. NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants. Epilepsy Research 1990; 5: 177-184.
18. DeGiorgio, C. M., Tomiyasu, U., Gott, P. S. and Treiman, D. M. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia 1992; 33: 23-27.
19. Clifford, D. B., Olney, J. W., Benz, A. M., Fuller, T. A. and Zorumski, C. F. Ketamine, phencyclidine and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990; 31: 382-390.
20. Fujikawa, D. G., Daniels, A. H. and Kim, J. S. The competitive NMDA receptor antagonist CGP 40 116 protects against status epilepticus-induced neuronal damage. Epilepsy Research 1994; 17: 207-219.
21. Wasterlain, C. G., Fujikawa, D. G., Penix, L. and Sankar, R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34 (Suppl. 1): S37-S53.
22. Goodman, L. S. and Gilman, A. G. General anesthetics. In: The Pharmacological Basis of Therapeutics (Eds A. G. Gilman, L. S. Goodman, T. W. Rall and F. Murad). New York, Macmillan Publishing Company, 1985: pp. 276-301.